Thorax, Vol 52, 1030-1035, Copyright © 1997 by Thorax.

Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist

TF Reiss, JB Hill, E Harman, J Zhang, WK Tanaka, E Bronsky, D Guerreiro and L Hendeles
Department of Pulmonary/Immunology and Biostatistics, Merck Research Laboratories, Rahway, New Jersey 07065, USA.

BACKGROUND: A study was undertaken to determine whether montelukast, a new potent cysteinyl leukotriene receptor antagonist, attenuates exercise-induced bronchoconstriction. The relationship between the urinary excretion of LTE4 and exercise-induced bronchoconstriction was also investigated. METHODS: Nineteen non-smoking asthmatic patients with a forced expiratory volume in one second (FEV1) of > or = 65% of the predicted value and a reproducible fall in FEV1 after exercise of at least 20% were enrolled. Subjects received placebo and montelukast 100 mg once daily in the evening or 50 mg twice daily, each for two days, in a three-period, randomised, double blind, crossover design. In the evening, approximately 20-24 hours after the once daily dose or 12 hours after the twice daily dose, a standardised exercise challenge was performed. Data from 14 patients were available for complete analysis. RESULTS: The mean (SD) maximal percentage decrease in FEV1 after exercise was 29.6 (16.0), 17.1 (8.2), and 14.0 (9.4) for placebo, once daily, and twice daily regimens, respectively. The mean (95% CI) percentage protection was 37 (15 to 59) for the group who received 50 mg twice daily and 50 (31 to 69) for those who received 100 mg once daily. Active treatments were not different from each other. The mean (SD) plasma concentrations of montelukast were higher after the twice daily regimen (1.27 (0.81) microgram/ml) than after the once daily regimen (0.12 (0.09) microgram/ml); there was no correlation between the percentage protection against exercise-induced bronchoconstriction and plasma concentrations. After exercise urinary excretion of LTE4 increased significantly during placebo treatment (from 34.3 to 73.7 pg/mg creatinine; p < 0.05) but did not correlate with the extent of exercise-induced bronchoconstriction. CONCLUSIONS: Montelukast protects similarly against exercise-induced bronchoconstriction between plasma concentrations of 0.12 and 1.27 micrograms/ml. The increase in the urinary excretion of LTE4 after exercise and the protection from exercise-induced bronchoconstriction with a cysteinyl leukotriene receptor antagonist provide further evidence of the role of leukotrienes in the pathogenesis of exercise-induced bronchoconstriction.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• del Giudice, M. M., Pezzulo, A., Capristo, C., Alterio, E., Caggiano, S., de Benedictis, D., Capristo, A. F. (2009). Leukotriene modifiers in the treatment of asthma in children. Ther Adv Respir Dis 3: 245-251 [Abstract]  
• Robertson, C. F., Price, D., Henry, R., Mellis, C., Glasgow, N., Fitzgerald, D., Lee, A. J., Turner, J., Sant, M. (2007). Short-Course Montelukast for Intermittent Asthma in Children: A Randomized Controlled Trial. Am. J. Respir. Crit. Care Med. 175: 323-329 [Abstract] [Full Text]  
• de Benedictis, F. M., del Giudice, M. M., Forenza, N., Decimo, F., de Benedictis, D., Capristo, A. (2006). Lack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children. Eur Respir J 28: 291-295 [Abstract] [Full Text]  
• Hallstrand, T. S., Moody, M. W., Wurfel, M. M., Schwartz, L. B., Henderson, W. R. Jr., Aitken, M. L. (2005). Inflammatory Basis of Exercise-induced Bronchoconstriction. Am. J. Respir. Crit. Care Med. 172: 679-686 [Abstract] [Full Text]  
• Coreno, A., Skowronski, M., West, E., El-Ekiaby, A., McFadden, E.R. Jr (2005). Bronchoprotective Effects of Single Doses of Salmeterol Combined With Montelukast in Thermally Induced Bronchospasm. Chest 127: 1572-1578 [Abstract] [Full Text]  
• Busse, W., Kraft, M. (2005). Cysteinyl Leukotrienes in Allergic Inflammation: Strategic Target for Therapy. Chest 127: 1312-1326 [Abstract] [Full Text]  
• Currie, G.P., Srivastava, P., Dempsey, O.J., Lee, D.K.C. (2005). Therapeutic modulation of allergic airways disease with leukotriene receptor antagonists. QJM 98: 171-182 [Abstract] [Full Text]  
• Green, S A, Malice, M-P, Tanaka, W, Tozzi, C A, Reiss, T F (2004). Increase in urinary leukotriene LTE4 levels in acute asthma: correlation with airflow limitation. Thorax 59: 100-104 [Abstract] [Full Text]  
• Mickleborough, T. D., Murray, R. L., Ionescu, A. A., Lindley, M. R. (2003). Fish Oil Supplementation Reduces Severity of Exercise-induced Bronchoconstriction in Elite Athletes. Am. J. Respir. Crit. Care Med. 168: 1181-1189 [Abstract] [Full Text]  
• Brannan, J.D., Gulliksson, M., Anderson, S.D., Chew, N., Kumlin, M. (2003). Evidence of mast cell activation and leukotriene release after mannitol inhalation. Eur Respir J 22: 491-496 [Abstract] [Full Text]  
• Joos, G.F., O'Connor, B. (2003). Indirect airway challenges. Eur Respir J 21: 1050-1068 [Abstract] [Full Text]  
• Sabater, J. R., Wanner, A., Abraham, W. M. (2002). Montelukast Prevents Antigen-induced Mucociliary Dysfunction in Sheep. Am. J. Respir. Crit. Care Med. 166: 1457-1460 [Abstract] [Full Text]  
• Terashima, T., Amakawa, K., Matsumaru, A., Yamaguchi, K. (2002). Correlation Between Cysteinyl Leukotriene Release From Leukocytes and Clinical Response to a Leukotriene Inhibitor. Chest 122: 1566-1570 [Abstract] [Full Text]  
• Wetter, T. J., Xiang, Z., Sonetti, D. A., Haverkamp, H. C., Rice, A. J., Abbasi, A. A., Meyer, K. C., Dempsey, J. A. (2002). Role of lung inflammatory mediators as a cause of exercise-induced arterial hypoxemia in young athletes. J. Appl. Physiol. 93: 116-126 [Abstract] [Full Text]  
• Mickleborough, T. D., Gotshall, R. W., Rhodes, J., Tucker, A., Cordain, L. (2001). Elevating dietary salt exacerbates hyperpnea-induced airway obstruction in guinea pigs. J. Appl. Physiol. 91: 1061-1066 [Abstract] [Full Text]  
• Salvi, S. S., Krishna, M. T., Sampson, A. P., Holgate, S. T. (2001). The Anti-inflammatory Effects of Leukotriene-Modifying Drugs and Their Use in Asthma. Chest 119: 1533-1546 [Abstract] [Full Text]  
• Bisgaard, H. (2001). Leukotriene Modifiers in Pediatric Asthma Management. Pediatrics 107: 381-390 [Abstract] [Full Text]  
• FIGUEROA, D. J., BREYER, R. M., DEFOE, S. K., KARGMAN, S., DAUGHERTY, B. L., WALDBURGER, K., LIU, Q., CLEMENTS, M., ZENG, Z., O'NEILL, G. P., JONES, T. R., LYNCH, K. R., AUSTIN, C. P., EVANS, J. F. (2001). Expression of the Cysteinyl Leukotriene 1 Receptor in Normal Human Lung and Peripheral Blood Leukocytes. Am. J. Respir. Crit. Care Med. 163: 226-233 [Abstract] [Full Text]  
• Dempsey, O J (2000). Leukotriene receptor antagonist therapy. Postgrad. Med. J. 76: 767-773 [Abstract] [Full Text]  
• Freed, A. N., McCulloch, S., Wang, Y. (2000). Eicosanoid and muscarinic receptor blockade abolishes hyperventilation-induced bronchoconstriction. J. Appl. Physiol. 89: 1949-1955 [Abstract] [Full Text]  
• GAUVREAU, G. M., RONNEN, G. M., WATSON, R. M., O'BYRNE, P. M. (2000). Exercise-induced Bronchoconstriction Does Not Cause Eosinophilic Airway Inflammation or Airway Hyperresponsiveness in Subjects with Asthma. Am. J. Respir. Crit. Care Med. 162: 1302-1307 [Abstract] [Full Text]  
• KUMLIN, M. (2000). Measurement of Leukotrienes in Humans. Am. J. Respir. Crit. Care Med. 161: S102-106 [Full Text]  
• Edelman, J. M., Turpin, J. A., Bronsky, E. A., Grossman, J., Kemp, J. P., Ghannam, A. F., DeLucca, P. T., Gormley, G. J., Pearlman, D. S., for the Exercise Study Group*, (2000). Oral Montelukast Compared with Inhaled Salmeterol To Prevent Exercise-Induced Bronchoconstriction: A Randomized, Double-Blind Trial. ANN INTERN MED 132: 97-104 [Abstract] [Full Text]  
• Crapo, R. (2000). Guidelines for Methacholine and Exercise Challenge Testing---1999 . THIS OFFICIAL STATEMENT OF THE AMERICAN THORACIC SOCIETY WAS ADOPTED BY THE ATS BOARD OF DIRECTORS, JULY 1999. Am. J. Respir. Crit. Care Med. 161: 309-329 [Full Text]  
• PAVORD, I. D., WARD, R., WOLTMANN, G., WARDLAW, A. J., SHELLER, J. R., DWORSKI, R. (1999). Induced Sputum Eicosanoid Concentrations in Asthma. Am. J. Respir. Crit. Care Med. 160: 1905-1909 [Abstract] [Full Text]  
• Freed, A. N., Wang, Y., McCulloch, S., Myers, T., Suzuki, R. (1999). Mucosal injury and eicosanoid kinetics during hyperventilation-induced bronchoconstriction. J. Appl. Physiol. 87: 1724-1733 [Abstract] [Full Text]  
• Drazen, J. M., Israel, E., O'Byrne, P. M. (1999). Treatment of Asthma with Drugs Modifying the Leukotriene Pathway. NEJM 340: 197-206 [Full Text]  
• Leff, J. A., Busse, W. W., Pearlman, D., Bronsky, E. A., Kemp, J., Hendeles, L., Dockhorn, R., Kundu, S., Zhang, J., Seidenberg, B. C., Reiss, T. F. (1998). Montelukast, a Leukotriene-Receptor Antagonist, for the Treatment of Mild Asthma and Exercise-Induced Bronchoconstriction. NEJM 339: 147-152 [Abstract] [Full Text]